

Felica Cosman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9362003/felica-cosman-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

114
papers

14,040
citations

47
h-index

117
g-index

117
ext. papers

16,025
ext. citations

7.1
avg, IF

6.12
L-index

#	Paper	IF	Citations
114	Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , 2007 , 356, 1809-22	59.2	2094
113	Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporosis International</i> , 2014 , 25, 2359-81	5.3	1775
112	Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1-23	6.3	935
111	Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2267-94	6.3	840
110	Romosozumab Treatment in Postmenopausal Women with Osteoporosis. <i>New England Journal of Medicine</i> , 2016 , 375, 1532-1543	59.2	725
109	Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. <i>Lancet, The</i> , 1997 , 350, 550-5	40	638
108	Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 1846-53	6.3	495
107	Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 722-33	27.4	452
106	The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 243-54	6.3	397
105	Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000 , 85, 3069-76	5.6	280
104	Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 503-11	6.3	256
103	Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 925-31	6.3	241
102	A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 366-73	6.3	218
101	Daily and cyclic parathyroid hormone in women receiving alendronate. <i>New England Journal of Medicine</i> , 2005 , 353, 566-75	59.2	216
100	Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1150-6	5.6	212
99	Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 495-502	6.3	205
98	Fragility fractures of the hip and femur: incidence and patient characteristics. <i>Osteoporosis International</i> , 2010 , 21, 399-408	5.3	201

97	Bone mass and body composition in normal women. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 55-63.	6.3	154
96	The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 934-44	6.3	152
95	Fracture history and bone loss in patients with MS. <i>Neurology</i> , 1998 , 51, 1161-5	6.5	151
94	Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 151-8	5.6	145
93	Resistance to bone resorbing effects of PTH in black women. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 958-66	6.3	142
92	Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 157, 1892-9	10.2	142
91	Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3772-80	5.6	134
90	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 198-202	6.3	132
89	Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999 , 84, 3076-81	5.6	116
88	Radiographic absorptiometry: a simple method for determination of bone mass. <i>Osteoporosis International</i> , 1991 , 2, 34-8	5.3	108
87	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 1393-9	6.3	103
86	Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 200-210	6.4	96
85	High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1097-105	6.3	96
84	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 3-10	6.3	94
83	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2949-2957	5.6	90
82	Determinants of stress fracture risk in United States Military Academy cadets. <i>Bone</i> , 2013 , 55, 359-66	4.7	90
81	Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 4546-54	5.6	89
80	Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. <i>Journal of Bone and Mineral Research</i> , 1998 , 13, 1051-5	6.3	88

79	Bone density change and biochemical indices of skeletal turnover. <i>Calcified Tissue International</i> , 1996 , 58, 236-43	3.9	88
78	Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. <i>Calcified Tissue International</i> , 1998 , 62, 475-80	3.9	81
77	Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 963-74	6.3	75
76	FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1219-1226	6.3	73
75	Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1328-36	6.3	69
74	Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. <i>Thrombosis Research</i> , 2005 , 116, 1-13	8.2	67
73	Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 948-57	6.3	66
72	Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. <i>Current Osteoporosis Reports</i> , 2014 , 12, 385-95	5.4	60
71	Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 17-23	6.3	57
70	Spine fracture prevalence in a nationally representative sample of US women and men aged ≥0 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014. <i>Osteoporosis International</i> , 2017 , 28, 1857-1866	5.3	56
69	Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1033-1040	6.3	48
68	Goal-directed treatment of osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 433-8	6.3	47
67	Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991 , 73, 1345-51	5.6	47
66	Romsozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1407-1416	6.3	44
65	Vitamin D economy in blacks. <i>Journal of Bone and Mineral Research</i> , 2007 , 22 Suppl 2, V34-8	6.3	42
64	Combination therapy for osteoporosis: a reappraisal. <i>BoneKEy Reports</i> , 2014 , 3, 518		40
63	Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. <i>Osteoporosis International</i> , 2008 , 19, 529-35	5.3	40
62	Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1110-5	6.3	39

61	Relationships between quantitative histological measurements and noninvasive assessments of bone mass. <i>Bone</i> , 1992 , 13, 237-42	4.7	36
60	Effects of estrogen on response to edetic acid infusion in postmenopausal osteoporotic women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994 , 78, 939-43	5.6	32
59	Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2769-76	5.6	29
58	Biochemical responses of bone metabolism to 1,25-dihydroxyvitamin D administration in black and white women. <i>Osteoporosis International</i> , 2000 , 11, 271-7	5.3	29
57	Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1518-26	6.3	29
56	Effect of Teriparatide on Bone Formation in the Human Femoral Neck. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1498-505	5.6	26
55	Therapeutic potential of parathyroid hormone. <i>Current Osteoporosis Reports</i> , 2004 , 2, 5-11	5.4	24
54	Comparative assessment of bone mineral density of the forearm using single photon and dual X-ray absorptiometry. <i>Calcified Tissue International</i> , 1992 , 51, 352-5	3.9	24
53	Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 702-12	6.3	22
52	Selective estrogen-receptor modulators. <i>Clinics in Geriatric Medicine</i> , 2003 , 19, 371-9	3.8	22
51	Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. <i>Osteoporosis International</i> , 2020 , 31, 1025-1048	5.3	20
50	Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. <i>Menopause</i> , 2018 , 25, 767-771	2.5	20
49	A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates. <i>Osteoporosis International</i> , 2016 , 27, 377-86	5.3	18
48	Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. <i>Endocrine Practice</i> , 2009 , 15, 483-93	3.2	18
47	T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1333-1342	6.3	18
46	ANABOLIC THERAPY AND OPTIMAL TREATMENT SEQUENCES FOR PATIENTS WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. <i>Endocrine Practice</i> , 2020 ,	3.2	17
45	Results of a fracture liaison service on hip fracture patients in an open healthcare system. <i>Aging Clinical and Experimental Research</i> , 2017 , 29, 331-334	4.8	16
44	Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2019 , 30, 1187-1194	5.3	15

43	Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1282-1288	6.3	15
42	Long-term treatment strategies for postmenopausal osteoporosis. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 420-426	5.3	15
41	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 810-816	6.3	15
40	Changes in vitamin D metabolites during teriparatide treatment. <i>Bone</i> , 2012 , 50, 1368-71	4.7	13
39	Relationship between growth hormone in vivo bioactivity, the insulin-like growth factor-I system and bone mineral density in young, physically fit men and women. <i>Growth Hormone and IGF Research</i> , 2008 , 18, 439-445	2	13
38	Anabolic therapy for osteoporosis: parathyroid hormone. <i>Current Rheumatology Reports</i> , 2006 , 8, 63-9	4.9	13
37	Abaloparatide: a new anabolic therapy on the horizon. <i>BoneKEy Reports</i> , 2015 , 4, 661		12
36	Anabolic therapy for osteoporosis: parathyroid hormone. <i>Current Osteoporosis Reports</i> , 2005 , 3, 143-9	5.4	12
35	Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998 , 83, 788-90	5.6	12
34	Parathyroid hormone secretory response to EDTA-induced hypocalcemia in black and white premenopausal women. <i>Calcified Tissue International</i> , 1999 , 65, 257-61	3.9	12
33	Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 219-225	6.3	11
32	Eating disorders, menstrual dysfunction, weight change and DMPA use predict bone density change in college-aged women. <i>Bone</i> , 2016 , 84, 113-119	4.7	10
31	Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women. <i>Bone</i> , 2019 , 120, 246-253	4.7	10
30	Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. <i>Clinical Therapeutics</i> , 2007 , 29, 1116-27	3.5	9
29	The evolving role of anabolic therapy in the treatment of osteoporosis. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 376-380	5.3	9
28	Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 594-600	6.3	8
27	Spine fracture prevalence in a nationally representative sample of US women and men aged 40-74 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014---supplementary presentation. <i>Osteoporosis International</i> , 2017 , 28, 2319-2320	5.3	7
26	Vertebral fracture assessment (VFA) for osteoporosis screening in US postmenopausal women: is it cost-effective?. <i>Osteoporosis International</i> , 2020 , 31, 2321-2335	5.3	7

25	Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	6
24	Bone density change and biochemical indices of skeletal turnover 1996 , 58, 236		5
23	Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?. <i>Current Osteoporosis Reports</i> , 2021 , 19, 189-205	5.4	5
22	Chapter 51. Parathyroid Hormone Treatment for Osteoporosis 244-249		5
21	No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients. <i>Bone Reports</i> , 2020 , 12, 100253	2.6	4
20	Abaloparatide followed by alendronate in women 80 years with osteoporosis: post hoc analysis of ACTIVExtend. <i>Menopause</i> , 2020 , 27, 1137-1142	2.5	3
19	Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1861-1872	2.5	3
18	Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. <i>Bone</i> , 2020 , 136, 115373	4.7	2
17	Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. <i>Advances in Therapy</i> , 2021 , 39, 58	4.1	2
16	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1225-1234	6.3	2
15	Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial. <i>Osteoporosis International</i> , 2021 , 1	5.3	2
14	Romosozumab and antiresorptive treatment: the importance of treatment sequence.. <i>Osteoporosis International</i> , 2022 , 1	5.3	2
13	Parathyroid hormone and abaloparatide treatment for osteoporosis. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2018 , 3, 61-67	1.7	1
12	Hypercalcaemia causing declining cognitive function in a head injured patient. <i>Brain Injury</i> , 1989 , 3, 315-8.	8.1	1
11	Abnormal microarchitecture and stiffness in postmenopausal women with isolated osteoporosis at the 1/3 radius. <i>Bone</i> , 2020 , 132, 115211	4.7	1
10	Early changes in bone turnover and bone mineral density after discontinuation of long-term oral bisphosphonates: a post hoc analysis. <i>Osteoporosis International</i> , 2021 , 32, 1879-1888	5.3	1
9	Unmasking romosozumab: response to comments by Uzoigwe et al. <i>Osteoporosis International</i> , 2017 , 28, 2021-2022	5.3	0
8	Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck.. <i>Bone</i> , 2022 , 116342	4.7	0

- 7 Long-term treatment strategies and goal-directed therapy **2021**, 1867-1872 0
- 6 Measuring serum calcium before and after teriparatide treatment: authors' response. *Osteoporosis International*, **2008**, 19, 1809-1809 5.3
- 5 Anabolic therapy for osteoporosis: Parathyroid hormone. *Current Osteoporosis Reports*, **2005**, 3, 143-149 5.4
- 4 Relationship Between Bioassayable Growth Hormone, The Insulin-Like Growth Factor-I System and Bone Mineral Density in Men and Women. *FASEB Journal*, **2007**, 21, A1421 0.9
- 3 Romosozumab for the treatment of postmenopausal osteoporosis **2021**, 1827-1833
- 2 Teriparatide and abaloparatide treatment for osteoporosis **2021**, 1757-1769
- 1 Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals. *JBMR Plus*, **2021**, 5, e10546 3.9